Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Buckley Sean D.
 2. Date of Event Requiring Statement (Month/Day/Year)
06/19/2018		 3. Issuer Name and Ticker or Trading Symbol
Fibrocell Science, Inc. [FCSC]
(Last)
(First)
(Middle)
FIBROCELL SCIENCE, INC., 405 EAGLEVIEW BLVD		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

EXTON, PA 19341		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock   (1) 01/14/2021 Common Stock 200 $ 232.5 D  
Option to Purchase Common Stock   (2) 07/19/2023 Common Stock 334 $ 82.35 D  
Option to Purchase Common Stock   (3) 04/01/2025 Common Stock 1,000 $ 63.6 D  
Option to Purchase Common Stock   (4) 09/27/2026 Common Stock 2,229 $ 11.25 D  
Option to Purchase Common Stock   (5) 03/16/2027 Common Stock 4,000 $ 11.25 D  
Option to Purchase Common Stock   (6) 01/25/2028 Common Stock 5,000 $ 3.45 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Buckley Sean D.
FIBROCELL SCIENCE, INC.
405 EAGLEVIEW BLVD
EXTON, PA 19341		       See Remarks  

Signatures

/s/ Sean D. Buckley 06/27/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option vested as follows: (i) 100 shares on January 14, 2011 and (ii) 50 shares on each of January 14, 2012 and January 14, 2013.
(2) The option vested in four equal installments on July 19, 2013, July 19, 2014, July 19, 2015 and July 19, 2016.
(3) The option vests in four equal installments on April 1, 2016, April 1, 2017, April 1, 2018 and April 1, 2019 provided the reporting person is employed by Fibrocell Science, Inc., (the "Company") on each vesting date.
(4) The option vests as follows (i) 558 shares on September 27, 2017 and (ii) the remaining shares in twelve equal quarterly installments beginning on December 27, 2017 and ending on September 27, 2020 provided the reporting person is employed by the Company on each vesting date.
(5) The option vests as follows: (i) 1,000 shares on March 16, 2018 and (ii) the remaining shares in twelve equal quarterly installments beginning on June 16, 2018 and ending on March 16, 2021 provided the reporting person is employed by the Company on each vesting date.
(6) The option vests as follows: (i) 1,250 shares on January 25, 2019 and (ii) the remaining shares in twelve equal quarterly installments beginning on April 25, 2019 and ending on January 25, 2022 provided the reporting person is employed by the Company on each vesting date.
 
Remarks:
Vice President of Business Administration and Corporate Secretary

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.